Coronavirus disease 2019 (Covid-19) and cardiovascular disease: A viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection

Journal of the American Heart Association

Volumn 9, Issue 7, 2020, Pages

  Guo, Junyi ^a   Huang, Zheng ^a   Lin, Li ^a   Lv, Jiagao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

ACEI ARB; Angiotensin converting enzyme 2; Cardiovascular disease; COVID 19; SARS CoV 2

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN FC FRAGMENT; RECOMBINANT ANGIOTENSIN CONVERTING ENZYME 2;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CORONAVIRUS DISEASE 2019; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART INJURY; HUMAN; INFECTION RISK; NOTE; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; BETACORONAVIRUS; CORONAVIRINAE; CORONAVIRUS INFECTION; PANDEMIC; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS PNEUMONIA;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BETACORONAVIRUS; CARDIOVASCULAR DISEASES; CORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85082791374     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.120.016219     Document Type: Note

References (20)

1. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1–10. [Epub ahead of print].
2. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pohlmann S. Susceptibility to SARS coronavirus S proteindriven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun. 2004;319:1216–1221.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;e201585:E1–E9. [Epub ahead of print].
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2002032. Accessed March 22, 2020. [Epub ahead of print].
6. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensinconverting enzyme 2. Circulation. 2005;111:2605–2610.
7. Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, Hoffman A, Abassi Z. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol. 2005;289:H1351–H1358.
8. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970–976.
9. Lia Y, Cheng X, Zeng Q, Chen Z, Wang Z, Yuan J, Wang X, Zhou Z, Wei Y, Cao G. Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei province. J Clin Cardiol. 2020;36:201–203. Available at: http://kns.cnki.net/kcms/detai​l/42.1130.R.20200​221.0950. 001.html. Accessed March 22, 2020.
10. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879.
11. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364–374.
12. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev. 2018;98:505–553.
13. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2001316. Accessed March 22, 2020. [Epub ahead of print].
14. Schouten LR, van Kaam AH, Kohse F, Veltkamp F, Bos LD, de Beer FM, van Hooijdonk RT, Horn J, Straat M, Witteveen E, et al. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study. Ann Intensive Care. 2019;9:55.
15. Chu CM, Poon LL, Cheng VC, Chan KS, Hung IF, Wong MM, Chan KH, Leung WS, Tang BS, Chan VL, et al. Initial viral load and the outcomes of SARS. CMAJ. 2004;171:1349–1352.
16. Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care. 2017;21:305.
17. Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21:234.
18. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, Butany J. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39:618–625.
19. Liu X, Wang R, Qu G, Wang Y, Liu P, Zhu Y, Fei G, Ren L, Zhou Y, Liu L. Histological findings of COVID-19 based on autopsy: a case report. J Forensic Med. 2020;36:1–3. Available at: http://www.fyxzz.cn/CN/artic​le/downl​oadAr​ ticle​File.do?attac​hType​=PDF&id=23213. Accessed March 22, 2020.
20. Lei C, Fu W, Qian K, Li T, Zhang S, Ding M, Hu S. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. bioRxiv. 2020. DOI: 10.1101/2020.02.01.929976. Accessed March 22, 2020.